Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Immune System Diseases: Page 2
Sequencing seeks to stay ahead of new COVID-19 surges
By
Alice Kan
Sequencing has been an essential tool for the development of strategies and therapeutics in the fight against COVID-19, and sequencing-based rapid and high-throughput diagnostics for COVID-19 are in development. Sequencing technology suppliers are collaborating with researchers to develop sequencing-based diagnostic tools. For example, several groups are using Illumina's next-generation sequencing (NGS) technology to develop ultrahigh-throughput COVID-19 diagnostic testing.
June 7, 2020
Adaptive Biotechnologies joins forces with Microsoft on virtual COVID-19 study
By
LabPulse.com staff writers
The study is set to enroll 1,000 participants in select U.S. metropolitan areas impacted by COVID-19, according to the companies. LabCorp's Covance drug development business will manage the collection of blood samples and nose and throat swabs from participants in their homes.
May 4, 2020
Industry roundup: Oncology dominates noncoronavirus IVD news
By
Bruce Carlson
There's no doubt that COVID-19 tests remain a focal point for research and development -- IVD manufacturers have released scores of COVID-19 tests in the U.S. and Europe, as the decline in elective procedures dragged down demand for traditional diagnostics. But companies increasingly are announcing new non-COVID-19 innovations designed to help them stay competitive for when reopening occurs. We have also seen some merger activity, though reduced from the prepandemic days.
April 30, 2020
Jury is still out on SARS-CoV-2 intermediate host
By
Samantha Black, PhD
One researcher from the University of Ottawa provides genomic evidence that dogs may be an intermediate carrier, while another study from Chinese researchers suggests that canines would be a poor transmitter of the virus.
April 16, 2020
Can the reality of coronavirus antibody tests live up to hype?
By
Emily Hayes and Bruce Carlson
But not so fast. Lab medicine professionals are cautioning about important caveats:
April 5, 2020
Do patients still have COVID-19 after symptoms resolve?
By
Kate Madden Yee
Researchers found that patients treated for mild COVID-19 still had the virus for up to eight days after symptoms resolved -- a result that underscores the difficulty of curbing the disease.
March 29, 2020
Blood marker may predict kidney transplant failure risk
By
Kate Madden Yee
The results could help clinicians better intervene before patients experience transplant rejection, wrote corresponding author Nicolas Degauque, PhD, of the Université de Nantes, France, and colleagues.
March 12, 2020
Study identifies risk factors for death from coronavirus
By
Abraham Kim
In the observational study, Dr. Bin Cao of Capital Medical University and colleagues from China examined the data of 191 patients with confirmed COVID-19 at two different hospitals. The median age of the patients was 56 and nearly 30% died in the hospitals. They also had various comorbidities, the most common being hypertension (30% of patients), diabetes (19%), and coronary artery disease (8%).
March 10, 2020
CRISPR proteins lead to novel POC diagnostics
By
Joseph Constance
CRISPR (clustered regularly interspaced short palindromic repeats) represents a bacterial immune system that contains a programmable protein able to cut DNA or RNA. With this technology, genes can be edited and modified in living cells and organisms. While much effort has gone into developing CRISPR to treat disease, CRISPR is also a platform for diagnostics.
February 9, 2020
Blood test helps gauge patients' CSVD risk
By
LabPulse.com staff writers
The research could help develop a "novel diagnostic test that clinicians can start to use as a quantitative measure of brain health in people who are at risk of developing cerebral small vessel disease," lead author Dr. Jason Hinman said in a statement released by the university.
February 4, 2020
Speedy coronavirus tests | Making the most of mass spectrometry | Blood test foresees kidney injury
By
Emily Hayes
Dear LabPulse Member,
February 3, 2020
Laboratories, IVD vendors get to work on novel coronavirus
By
Bruce Carlson
The first known cases emerged in December 2019 and were traced to an animal market in Wuhan, China, from patients who are believed to have come in contact with live animals that were infected. Wuhan is a large hub city with a population of 11Â million, located 500 miles from Shanghai. At the time of writing, 81 people had died from the virus and 2,700 were infected, with reports changing rapidly. The spread of the disease to other nations including the U.S. is a top story in the news media and, of course, a concern to laboratorians.
January 27, 2020
Previous Page
Page 2 of 3
Next Page